Oral Nigella sativa seed-oil supplementation × Relief of WOMAC pain and functional limitation in knee osteoarthritis

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich knee-osteoarthritis question is addressed?Required	The original claim concerns WOMAC pain/function relief in knee osteoarthritis. The principal endpoint is total WOMAC in a 1-month comparison of oral liquid seed oil. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis	Material needed: Original eligibility criteria and WOMAC endpoint tables are needed. Other joint diseases, routes, cartilage regeneration and drug replacement are excluded. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre oral liquid seed oil and other formulations distinguished?Required	The plant part/preparation is seed fixed oil and the formulation is oral liquid seed oil. Seed powder, aqueous extracts, ethanolic topical preparations, purified thymoquinone and combinations are not treated as the same product. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product	Material needed: Product identity, manufacture/extraction, standardized constituents and batch material are needed. Equivalence to other formulations is unverified. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhat are the dose, frequency and actual exposure?Required	The original dose is 2.5 mL every 8 hours. No daily total, active-constituent quantity or recommended dose is calculated or converted. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original administration and adherence for 2.5 mL every 8 hours	Material needed: Original administration records, active-constituent quantities, adherence and actual administration/discontinuation material are needed. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionWhat defines diagnosis and severity in the knee-osteoarthritis population?Required	The population is adults with knee osteoarthritis. The original research description states that rheumatoid arthritis evidence was excluded. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Adult diagnosis, imaging/symptom severity and baseline WOMAC	Material needed: Diagnosis/severity, baseline scores, age, comorbidity, eligibility criteria and arm-specific tables are needed. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhat is known about the matched-placebo arrangements?Required	The original use conditions specify matched placebo, and R01 is described as a randomized, double-blind, placebo-controlled trial. Actual placebo composition and common management are absent from the summary. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Placebo constituents, taste/odor, packaging and common management	Material needed: Original placebo/masking methods, management and adherence material are needed. Placebo matching and successful masking are not certified here. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionAre concomitant analgesics, exercise and other treatments distinguished?Required	The original key issue distinguishes WOMAC, VAS and analgesic use. The advertising assessment states that analgesic-replacement claims exceed the trial scope. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes	Material needed: Original analgesic maintenance/use, rescue-medication rules, exercise/rehabilitation and changes to additional treatment are needed. Efficacy is not extended to an isolated seed-oil effect or drug replacement. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWhat reporting units do the principal trial and review represent?Required	R01 is the 2022 Huseini original trial; R02 is the 2024 systematic review. The reports are not counted as independent original trials. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review	Material needed: The review’s included articles, registration, additional reports and links to R01 are needed. Recitation of the same original trial is unconfirmed. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhat arm-specific denominators are represented by 116 randomized participants?Required	R01 records 116 randomized participants and 52 versus 54 completers. Total randomization remains distinct from completion; completion counts are not converted into arm-specific randomized counts. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Total randomization and arm-specific randomized/analysis denominators	Material needed: Arm labels and correspondence with randomized, analyzed and completion counts, plus WOMAC analysis denominators, are needed. Missing-person counts and effects are not newly calculated. This records needed materials; no new research was executed.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionWhat is known about completers, missing data, withdrawals and analysis sets?Required	The 52 versus 54 counts describe completion. The retained sample description does not specify arm labels, ITT/completer analyses or withdrawal reasons. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers	Material needed: Original flow diagrams, exclusion/discontinuation reasons, missing WOMAC measurements, missing-data handling and sensitivity material are needed. Unread material is not converted into an absence of missing data. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionAre total WOMAC and its three domains distinguished?Required	The principal endpoint is total WOMAC with pain, stiffness and function domains. The original key issue distinguishes total score from the pain domain. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Separate scales/ranges/timing for total score, pain, stiffness and function	Material needed: Original scale versions, score ranges, assessment timing and effects/denominators for each domain are needed. Total-score percentage reduction is not replicated as values for all domains. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionWhat do the original WOMAC reductions represent?Required	R01 retains WOMAC reductions of 27.72±18.61% versus 1.34±2.31%, P<.001; the original record describes the exact between-group CI as unreported. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Arm-specific percentage reductions, original ± notation and measurement/calculation definitions	Material needed: Original definitions of means/dispersion, baseline/change values, denominators and statistical methods are needed. ± is not arbitrarily converted into CI/SE, and no new between-group difference is calculated. This records needed materials; no new research was executed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionAre the exact adjusted between-group difference and 95% CI available?Required	The original reader answer describes the exact adjusted between-group difference and 95% CI as unreported. The result table retains the original label that the exact between-group CI is unreported. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Adjusted/unadjusted between-group effects and 95% CI	Material needed: Original between-group analysis tables, adjustment variables, variance and CIs are needed. Unreported information in the original summary remains distinct from current external nonreading; numbers are not reverse-calculated. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionWhat endpoint and comparison does P<.001 concern?Required	P<.001 is retained with the original WOMAC percentage-reduction result. It is not replicated as a P value for VAS, all domains or long-term results. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original between-group WOMAC testing and multiplicity/analysis plans	Material needed: Original tests, primary endpoints/timing, multiplicity, analysis sets and adjustment arrangements are needed. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionAre 1-month results distinguished from sustained and post-discontinuation effects?Required	The original duration is 1 month of treatment and follow-up. The original rationale states that this is a symptom signal rather than cartilage protection or a sustained effect. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	The original 1 month of treatment/follow-up and separate later material	Material needed: Longer follow-up, post-discontinuation course and repeat trials of the same formulation are needed. A 1-month result is not converted into a long-term effect. This records needed materials; no new research was executed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionAre the original allocation and masking methods known?Required	R01 is described as a randomized, double-blind, placebo-controlled trial. Original methodological details, successful masking and suitability remain unverified here. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Random sequence, concealment and participant/assessor masking	Material needed: Original methods, registration/plans and masking material are needed. No formal RoB2 result or new suitability judgment is created. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionAre the prospective WOMAC hierarchy and reporting selection confirmed?Required	The stored evidence describes WOMAC as principal and VAS and other outcomes as secondary. Registration status is unconfirmed. The original prospective plan remains unread here. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Prospective plans for primary endpoints, domains, VAS and timing	Material needed: Registration, protocols/SAPs, original endpoint tables and all reported time points are needed. A summary selecting a principal outcome is not promoted to confirmed preregistration. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionIs concordant VAS direction retained as a separate endpoint?Supplementary	The original counterview describes concordant WOMAC and VAS directions. VAS is secondary; specific VAS values are absent from the retained result. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Separate VAS effects, CIs, denominators and timing	Material needed: Original VAS results and prospective hierarchy are needed. WOMAC reductions and gaps in P values/CIs are not transferred into VAS values. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionAre analgesic-use results separate from WOMAC?Supplementary	The original key issue distinguishes analgesic use from total score, pain and VAS. Structured evidence does not contain numeric analgesic-use results. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Rescue-medication definitions, timing and arm-specific effects/denominators	Material needed: Original amounts used, rescue-medication rules, prospective hierarchy and result tables are needed. An analgesic-replacement effect is not established. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionAre patient importance and responder effects known?Supplementary	The original grade rationale describes a positive patient-symptom-scale signal. Exact CIs, responder rates and prospective importance thresholds are absent from the structured summary. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	WOMAC importance thresholds and prospectively defined responder results	Material needed: Original importance criteria, responder definitions/denominators and CIs are needed. Percentage reduction alone is not used for a new judgment of clinically large effects or treatment success. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionWhat is the scope of the review’s 6 RCTs and 370 participants?Required	R02 records 6 RCTs and 370 participants, mixing oral and topical routes. These are not converted into 6 independent trials of oral liquid seed oil or WOMAC analysis denominators. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Included material and endpoint-specific denominators in the mixed oral/topical review	Material needed: Inclusion tables by route, formulation, original-trial family, endpoint and timing are needed. The 116 and 370 participants are not summed. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionIs the finding of a positive oral-oil result in one of two trials retained?Required	R02 records a positive oral-oil finding in one of two trials, with mixed other oral/topical results. This is not presented as confirmed replication of the same formulation. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Formulations, populations, timing and effects/CIs in the two oral-oil trials	Material needed: Identifiers, doses, endpoints/timing, effects, denominators and inclusion relationships for the two trials are needed. Numbers/CIs for another unidentified trial are not invented. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionAre topical oil, oral capsules and rheumatoid-arthritis material separated?Required	The original research description excludes topical oil/rheumatoid-arthritis material, while the original supplementary note states that topical oil and oral capsules are not identical replications. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Eligibility boundaries by route, formulation and disease	Material needed: Original review tables by route, formulation and disease are needed. These are not combined as independent replication or equivalence for this oral liquid seed oil. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre independent teams and unique trial/participant counts certified?Required	The original principal verdict retains a single principal study and limited replication. The current reports represent an original trial and a review; shared-trial correspondence is unconfirmed. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original-trial families and overlap/independence links for the same question	Material needed: Teams, institutions, funding, identical samples and original-trial/additional-report lists are needed. Final unique-trial and participant totals remain null. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionAre cartilage protection, disease modification and analgesic replacement separate questions?Supplementary	The original rationale/advertising assessment does not extend a 1-month symptom signal to cartilage protection, regeneration, disease modification or analgesic replacement. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement	Material needed: Direct comparisons of imaging/structural endpoints, long-term clinical course and drug replacement are needed. Those efficacy claims are not added here. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre the four channels of company involvement known separately?Required	R01 records unconfirmed funding/product-involvement details; R02 records differing funding across individual trials. Generic English funding wording remains distinct from complete item-specific material. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Trial/review-specific funding, product support, employee authorship and COI	Material needed: Original support, product provision, author affiliations and COI are needed. Unverified information is not converted into a noncommercial/independence strength. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionAre harm-collection methods, discontinuations and events known?Supplementary	The original safety label is Caution, and small trials cannot exclude rare adverse events or establish long-term safety. Specific harm-collection methods/event tables are absent from stored summaries. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Adverse-event definitions, collection, severity and original event tables	Material needed: Active/passive collection, events, discontinuations and missing-data material are needed. Unread material is not presented as an absence of adverse events. This records needed materials; no new research was executed.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionWhat are the harm denominators and exposure durations?Supplementary	The 116 randomized participants and 52 versus 54 completers do not establish safety denominators. Exposure for 1 month is not long-term harm evidence. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Safety denominators, actual administration and arm-specific events/exposure	Material needed: Arm-specific safety sets, administration/discontinuation, event counts, exposure time and control-group records are needed. No new incidence is calculated. This records needed materials; no new research was executed.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionWhat is known about concomitant medicines, other causes and event timing?Supplementary	The original safety description contains cautions calling for consultation during use of those medicines. This does not confirm actual drug-specific interactions or causal harms. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes	Material needed: Concomitant medicines, baseline diseases, event timing, changes, controls and post-discontinuation course are needed. New drug-specific causal judgments are not created. This records needed materials; no new research was executed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionAre long-term, rare and vulnerable-population harms verified?Supplementary	The original text retains consultation cautions for pregnancy/breastfeeding, children, liver/kidney disease and surgery, and the inability to exclude rare/long-term harms. This is not promoted to safety certification. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Independent harm reports, long-term/rare events, vulnerable groups and exposure	Material needed: Longer follow-up, vulnerable populations, independent reports and exposure/denominator material are needed. No new harm search or reassessment is performed. This records needed materials; no new research was executed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionAre actual stored-summary reading and original-source links distinguished?Required	The complete stored summary was read for preparation; the two PubMed URLs and review PMCID are retained records. External abstracts, full text, registration and protocols/SAPs remain unread here. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Access table for stored summaries, abstracts, full text, registration and protocols/SAPs	Material needed: External material remains unread before user-provided acquisition and review. A PMCID/URL alone is not promoted to access, reading or fulfilled conditions. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionAre generic English wording and the historical correction preserved?Supplementary	The correction records changes to 2 English-placeholder fields while preserving original values. Remaining generic English wording on sample size, results and funding is preserved in the original and is not presented as newly completed content review. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	The full Korean/English record and targets/limits of the 2026-09-14 correction	Material needed: The original correction-target comparison and external English texts remain unverified here. Current preparation remains distinct from historical verification wording. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionAre original grades, axes, evidence date and production distinguished?Required	C/50/Caution, original axes and the evidence date 2026-09-08 are retained. This preparation is not a new efficacy grade, independent certification or formal-method certification. R01 R02	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original C50, Caution, axes, evidence date and correction values	Material needed: New evidence, condition revisions and verdict changes are separate events after user review. Original dates are not converted into a current search end date or external-reading date. This records needed materials; no new research was executed.

No items match your search or filter.

32 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-08
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
Population: The population is adults with knee osteoarthritis. Details of diagnosis, imaging/symptom severity, baseline WOMAC, age, comorbidities and eligibility criteria remain unverified. Rheumatoid arthritis and other diseases remain distinct.
Ingredient, formulation and route: The intervention is oral liquid supplementation with Nigella sativa L. seed fixed oil. Product identity, extraction, standardized constituents and batch quality remain unverified. Topical oil, oral capsules, powder, aqueous extracts, purified thymoquinone and combinations are not treated as interchangeable.
Dose: The original dose is 2.5 mL every 8 hours. Actual administration, adherence, discontinuation and active-constituent quantities remain unverified. No new daily total, cumulative dose, active dose, optimal dose or recommended dose is calculated or converted into personal dosing instructions.
Comparator: The record describes comparison with matched placebo. Matching constituents, taste/odor, packaging, administration, common management, analgesics, exercise/rehabilitation and additional treatments by arm remains unverified.
Measured outcome: The selected endpoint is total WOMAC with pain, stiffness and function domains. Percentage reduction in the total, individual domains, VAS and analgesic use remain separate. Scale version, range, measurement, denominators, prospective hierarchy and importance thresholds remain unverified.
Duration: The original record describes 1 month of treatment and follow-up. Exact assessment visits, post-discontinuation course, longer follow-up and replication of the same formulation remain unverified. Duration is not converted into weeks or days, and sustained long-term effects are not established.
Questions outside this scope: The selected question concerns WOMAC pain/function relief in a comparison of oral liquid seed oil and matched placebo in adults with knee osteoarthritis. It is not extended to other routes, formulations or diseases, cartilage protection/regeneration, disease modification or analgesic replacement.; The existing C·50 points·Caution and B/P/R1/I1/E+/B2/C0 are retained. Historical cross-check wording is not presented as completed content review, formal-method execution or new independent clinical validation.; The 116 randomized participants remain distinct from 52 versus 54 completers. Arm-specific randomized/analyzed/completion correspondence is unconfirmed. The review’s 6 RCTs and 370 participants mix oral and topical routes, with overlap with the original trial unconfirmed. No new summation, missing/withdrawal count, denominator reconstruction or harm incidence is calculated.; WOMAC reductions of 27.72±18.61% versus 1.34±2.31%, P<.001, are retained as original reported values. The definition of ± and exact adjusted between-group effects/intervals remain unverified. Dispersion is not converted into CI/SE, and no new difference or responder rate is calculated.; Total WOMAC, pain/stiffness/function domains, VAS and analgesic use remain separate. The 1-month total-score result and P value are not replicated across all domains, other endpoints or longer follow-up, or interpreted as individual treatment success or cartilage regeneration.; The review records a positive oral-oil finding in one of two trials, with mixed other oral/topical findings. Confirmed replication of the same oral liquid formulation, independent-team replication, optimal dosing and unique-trial counts are not newly certified.; PMID36150238, DOI10.1016/j.ctcp.2022.101666, PMID38650731, PMCID PMC11033494 and DOI10.1002/hsr2.1989 are existing bibliography. Original-trial/review registration is unconfirmed; external abstracts, full texts, registration, protocols and analysis plans are unread. Acquisition, accessibility, reading and prespecification are not inferred from identifiers.; The original evidence date 2026-09-08, the correction date 2026-09-14 for 2 English-placeholder fields and the original production date 2026-10-06 are retained. Generic English evidence wording, funding descriptions and cautions are not promoted to actual full-text reading or certification of independence, harm collection or overall safety.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Huseini et al. 2022 · Trial of oral Nigella sativa seed oil and knee-osteoarthritis pain/function

PubMed

Material type: Retained description as a randomized, double-blind, placebo-controlled trial; actual allocation and masking procedures are not externally verified
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: WOMAC reductions 27.72±18.61% versus 1.34±2.31%, P<.001; retained record describes the exact between-group CI as unreported
Record level: These are existing reported values. The 116 randomized participants remain distinct from 52 versus 54 completers, with gaps in arm-specific analysis denominators, dispersion definitions and exact adjusted between-group effects/intervals. Unreported information in the original summary remains distinct from current external nonreading.
Study overlap and independent replication: Inclusion/overlap correspondence between the principal oral-liquid-seed-oil trial and the mixed oral/topical review is unconfirmed. Reports, original trials, independent teams and participant totals remain distinct; unique-trial and participant counts remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored summary was read for preparation. This does not establish acquisition/reading of article full text or clinical validation. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
External abstract	Original bibliography link only; external content unread	Unread; no access attempt	Unread	Only the identity link in the existing PubMed bibliography is connected. External abstract content reading and access testing were not performed. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
External full text	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Article full text is unacquired and unread. A bibliographic link is not presented as full-text acquisition or successful access. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
Registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original-trial/review registration identities and contents are unconfirmed and unread. Nonregistration, nonpublication and absence of prospective plans are not inferred. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
Protocols and analysis plans	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Protocols and analysis plans are unread. Endpoints, timing, denominators, missing data, multiplicity and exact effects/intervals are not verified or reverse-calculated. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.

R02 · 2024 · Systematic review of Nigella sativa and osteoarthritis

PubMed

Material type: Retained description as a systematic review including oral and topical studies; original included trials and route-specific correspondence are not externally verified
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: Positive oral-oil finding in one of two trials; mixed other oral/topical findings
Record level: The review’s 6 RCTs and 370 participants describe the original mixed-route scale. Inclusion/overlap of the principal original trial and independent replication of the same formulation remain unconfirmed. Original trials/participants are not summed, and effects/intervals for unidentified trials are not invented.
Study overlap and independent replication: Inclusion/overlap correspondence between the principal oral-liquid-seed-oil trial and the mixed oral/topical review is unconfirmed. Reports, original trials, independent teams and participant totals remain distinct; unique-trial and participant counts remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	The stored summary was read for preparation. This does not establish acquisition/reading of article full text or clinical validation. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
External abstract	Original bibliography link only; external content unread	Unread; no access attempt	Unread	Only the identity link in the existing PubMed bibliography is connected. External abstract content reading and access testing were not performed. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
External full text	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	PMCID PMC11033494 is an identifier retained in the original bibliography. Full-text acquisition, public availability, successful access and actual reading were not verified in this work. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
Registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Original-trial/review registration identities and contents are unconfirmed and unread. Nonregistration, nonpublication and absence of prospective plans are not inferred. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.
Protocols and analysis plans	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Protocols and analysis plans are unread. Endpoints, timing, denominators, missing data, multiplicity and exact effects/intervals are not verified or reverse-calculated. Existing bibliography is linked; external abstracts, full texts, registration, protocols and analysis plans are unread. A URL or identifier alone does not establish acquisition, accessibility, content reading, prespecification or fulfilled conditions. The date 2026-09-08 is the original evidence date. Material timestamps for stored summaries describe original production on 2026-10-06, not external reading. External-material timestamps and original review and verification dates remain unrecorded.

Report counts versus independent study counts

Inclusion/overlap correspondence between the principal oral-liquid-seed-oil trial and the mixed oral/topical review is unconfirmed. Reports, original trials, independent teams and participant totals remain distinct; unique-trial and participant counts remain unrecorded.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which knee-osteoarthritis question is addressed?

Required materials and conditions: Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis
Conditions for verification: Original records on Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N02 · Are oral liquid seed oil and other formulations distinguished?

Required materials and conditions: Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product
Conditions for verification: Original records on Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N03 · What are the dose, frequency and actual exposure?

Required materials and conditions: Original administration and adherence for 2.5 mL every 8 hours
Conditions for verification: Original records on Original administration and adherence for 2.5 mL every 8 hours must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Original administration and adherence for 2.5 mL every 8 hours is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N04 · What defines diagnosis and severity in the knee-osteoarthritis population?

Required materials and conditions: Adult diagnosis, imaging/symptom severity and baseline WOMAC
Conditions for verification: Original records on Adult diagnosis, imaging/symptom severity and baseline WOMAC must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Adult diagnosis, imaging/symptom severity and baseline WOMAC is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N05 · What is known about the matched-placebo arrangements?

Required materials and conditions: Placebo constituents, taste/odor, packaging and common management
Conditions for verification: Original records on Placebo constituents, taste/odor, packaging and common management must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Placebo constituents, taste/odor, packaging and common management is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N06 · Are concomitant analgesics, exercise and other treatments distinguished?

Required materials and conditions: Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes
Conditions for verification: Original records on Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N07 · What reporting units do the principal trial and review represent?

Required materials and conditions: Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review
Conditions for verification: Original records on Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N08 · What arm-specific denominators are represented by 116 randomized participants?

Required materials and conditions: Total randomization and arm-specific randomized/analysis denominators
Conditions for verification: Original records on Total randomization and arm-specific randomized/analysis denominators must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Total randomization and arm-specific randomized/analysis denominators is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N09 · What is known about completers, missing data, withdrawals and analysis sets?

Required materials and conditions: Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers
Conditions for verification: Original records on Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N10 · Are total WOMAC and its three domains distinguished?

Required materials and conditions: Separate scales/ranges/timing for total score, pain, stiffness and function
Conditions for verification: Original records on Separate scales/ranges/timing for total score, pain, stiffness and function must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Separate scales/ranges/timing for total score, pain, stiffness and function is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N11 · What do the original WOMAC reductions represent?

Required materials and conditions: Arm-specific percentage reductions, original ± notation and measurement/calculation definitions
Conditions for verification: Original records on Arm-specific percentage reductions, original ± notation and measurement/calculation definitions must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Arm-specific percentage reductions, original ± notation and measurement/calculation definitions is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N12 · Are the exact adjusted between-group difference and 95% CI available?

Required materials and conditions: Adjusted/unadjusted between-group effects and 95% CI
Conditions for verification: Original records on Adjusted/unadjusted between-group effects and 95% CI must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Adjusted/unadjusted between-group effects and 95% CI is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N13 · What endpoint and comparison does P<.001 concern?

Required materials and conditions: Original between-group WOMAC testing and multiplicity/analysis plans
Conditions for verification: Original records on Original between-group WOMAC testing and multiplicity/analysis plans must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Original between-group WOMAC testing and multiplicity/analysis plans is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N14 · Are 1-month results distinguished from sustained and post-discontinuation effects?

Required materials and conditions: The original 1 month of treatment/follow-up and separate later material
Conditions for verification: Original records on The original 1 month of treatment/follow-up and separate later material must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on The original 1 month of treatment/follow-up and separate later material is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N15 · Are the original allocation and masking methods known?

Required materials and conditions: Random sequence, concealment and participant/assessor masking
Conditions for verification: Original records on Random sequence, concealment and participant/assessor masking must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Random sequence, concealment and participant/assessor masking is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N16 · Are the prospective WOMAC hierarchy and reporting selection confirmed?

Required materials and conditions: Prospective plans for primary endpoints, domains, VAS and timing
Conditions for verification: Original records on Prospective plans for primary endpoints, domains, VAS and timing must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Prospective plans for primary endpoints, domains, VAS and timing is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N17 · Is concordant VAS direction retained as a separate endpoint?

Required materials and conditions: Separate VAS effects, CIs, denominators and timing
Conditions for verification: Original records on Separate VAS effects, CIs, denominators and timing must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Separate VAS effects, CIs, denominators and timing is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N18 · Are analgesic-use results separate from WOMAC?

Required materials and conditions: Rescue-medication definitions, timing and arm-specific effects/denominators
Conditions for verification: Original records on Rescue-medication definitions, timing and arm-specific effects/denominators must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Rescue-medication definitions, timing and arm-specific effects/denominators is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N19 · Are patient importance and responder effects known?

Required materials and conditions: WOMAC importance thresholds and prospectively defined responder results
Conditions for verification: Original records on WOMAC importance thresholds and prospectively defined responder results must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on WOMAC importance thresholds and prospectively defined responder results is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N20 · What is the scope of the review’s 6 RCTs and 370 participants?

Required materials and conditions: Included material and endpoint-specific denominators in the mixed oral/topical review
Conditions for verification: Original records on Included material and endpoint-specific denominators in the mixed oral/topical review must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Included material and endpoint-specific denominators in the mixed oral/topical review is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N21 · Is the finding of a positive oral-oil result in one of two trials retained?

Required materials and conditions: Formulations, populations, timing and effects/CIs in the two oral-oil trials
Conditions for verification: Original records on Formulations, populations, timing and effects/CIs in the two oral-oil trials must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Formulations, populations, timing and effects/CIs in the two oral-oil trials is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N22 · Are topical oil, oral capsules and rheumatoid-arthritis material separated?

Required materials and conditions: Eligibility boundaries by route, formulation and disease
Conditions for verification: Original records on Eligibility boundaries by route, formulation and disease must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Eligibility boundaries by route, formulation and disease is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N23 · Are independent teams and unique trial/participant counts certified?

Required materials and conditions: Original-trial families and overlap/independence links for the same question
Conditions for verification: Original records on Original-trial families and overlap/independence links for the same question must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Original-trial families and overlap/independence links for the same question is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N24 · Are cartilage protection, disease modification and analgesic replacement separate questions?

Required materials and conditions: Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement
Conditions for verification: Original records on Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N25 · Are the four channels of company involvement known separately?

Required materials and conditions: Trial/review-specific funding, product support, employee authorship and COI
Conditions for verification: Original records on Trial/review-specific funding, product support, employee authorship and COI must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Trial/review-specific funding, product support, employee authorship and COI is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N26 · Are harm-collection methods, discontinuations and events known?

Required materials and conditions: Adverse-event definitions, collection, severity and original event tables
Conditions for verification: Original records on Adverse-event definitions, collection, severity and original event tables must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Adverse-event definitions, collection, severity and original event tables is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N27 · What are the harm denominators and exposure durations?

Required materials and conditions: Safety denominators, actual administration and arm-specific events/exposure
Conditions for verification: Original records on Safety denominators, actual administration and arm-specific events/exposure must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Safety denominators, actual administration and arm-specific events/exposure is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N28 · What is known about concomitant medicines, other causes and event timing?

Required materials and conditions: Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes
Conditions for verification: Original records on Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N29 · Are long-term, rare and vulnerable-population harms verified?

Required materials and conditions: Independent harm reports, long-term/rare events, vulnerable groups and exposure
Conditions for verification: Original records on Independent harm reports, long-term/rare events, vulnerable groups and exposure must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Independent harm reports, long-term/rare events, vulnerable groups and exposure is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N30 · Are actual stored-summary reading and original-source links distinguished?

Required materials and conditions: Access table for stored summaries, abstracts, full text, registration and protocols/SAPs
Conditions for verification: Original records on Access table for stored summaries, abstracts, full text, registration and protocols/SAPs must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Access table for stored summaries, abstracts, full text, registration and protocols/SAPs is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N31 · Are generic English wording and the historical correction preserved?

Required materials and conditions: The full Korean/English record and targets/limits of the 2026-09-14 correction
Conditions for verification: Original records on The full Korean/English record and targets/limits of the 2026-09-14 correction must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Supplementary
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on The full Korean/English record and targets/limits of the 2026-09-14 correction is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

N32 · Are original grades, axes, evidence date and production distinguished?

Required materials and conditions: Original C50, Caution, axes, evidence date and correction values
Conditions for verification: Original records on Original C50, Caution, axes, evidence date and correction values must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Why this condition is needed: Material on Original C50, Caution, axes, evidence date and correction values is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 32 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which knee-osteoarthritis question is addressed?

Current findings: The original claim concerns WOMAC pain/function relief in knee osteoarthritis. The principal endpoint is total WOMAC in a 1-month comparison of oral liquid seed oil.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original eligibility criteria and WOMAC endpoint tables are needed. Other joint diseases, routes, cartilage regeneration and drug replacement are excluded.
Required materials and conditions: Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis
Materials to obtain first: Additional material needed: Original eligibility criteria and WOMAC endpoint tables are needed. Other joint diseases, routes, cartilage regeneration and drug replacement are excluded.
Further research: Material needed: Original eligibility criteria and WOMAC endpoint tables are needed. Other joint diseases, routes, cartilage regeneration and drug replacement are excluded. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Oral liquid seed oil versus matched placebo and 1-month WOMAC in adults with knee osteoarthritis is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N02 · Are oral liquid seed oil and other formulations distinguished?

Current findings: The plant part/preparation is seed fixed oil and the formulation is oral liquid seed oil. Seed powder, aqueous extracts, ethanolic topical preparations, purified thymoquinone and combinations are not treated as the same product.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Product identity, manufacture/extraction, standardized constituents and batch material are needed. Equivalence to other formulations is unverified.
Required materials and conditions: Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product
Materials to obtain first: Additional material needed: Product identity, manufacture/extraction, standardized constituents and batch material are needed. Equivalence to other formulations is unverified.
Further research: Material needed: Product identity, manufacture/extraction, standardized constituents and batch material are needed. Equivalence to other formulations is unverified. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Constituent/manufacturing information for Nigella sativa L. seed fixed oil as an oral liquid product is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N03 · What are the dose, frequency and actual exposure?

Current findings: The original dose is 2.5 mL every 8 hours. No daily total, active-constituent quantity or recommended dose is calculated or converted.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original administration records, active-constituent quantities, adherence and actual administration/discontinuation material are needed.
Required materials and conditions: Original administration and adherence for 2.5 mL every 8 hours
Materials to obtain first: Additional material needed: Original administration records, active-constituent quantities, adherence and actual administration/discontinuation material are needed.
Further research: Material needed: Original administration records, active-constituent quantities, adherence and actual administration/discontinuation material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Original administration and adherence for 2.5 mL every 8 hours must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original administration and adherence for 2.5 mL every 8 hours is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N04 · What defines diagnosis and severity in the knee-osteoarthritis population?

Current findings: The population is adults with knee osteoarthritis. The original research description states that rheumatoid arthritis evidence was excluded.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Diagnosis/severity, baseline scores, age, comorbidity, eligibility criteria and arm-specific tables are needed.
Required materials and conditions: Adult diagnosis, imaging/symptom severity and baseline WOMAC
Materials to obtain first: Additional material needed: Diagnosis/severity, baseline scores, age, comorbidity, eligibility criteria and arm-specific tables are needed.
Further research: Material needed: Diagnosis/severity, baseline scores, age, comorbidity, eligibility criteria and arm-specific tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Adult diagnosis, imaging/symptom severity and baseline WOMAC must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Adult diagnosis, imaging/symptom severity and baseline WOMAC is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N05 · What is known about the matched-placebo arrangements?

Current findings: The original use conditions specify matched placebo, and R01 is described as a randomized, double-blind, placebo-controlled trial. Actual placebo composition and common management are absent from the summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original placebo/masking methods, management and adherence material are needed. Placebo matching and successful masking are not certified here.
Required materials and conditions: Placebo constituents, taste/odor, packaging and common management
Materials to obtain first: Additional material needed: Original placebo/masking methods, management and adherence material are needed. Placebo matching and successful masking are not certified here.
Further research: Material needed: Original placebo/masking methods, management and adherence material are needed. Placebo matching and successful masking are not certified here. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Placebo constituents, taste/odor, packaging and common management must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Placebo constituents, taste/odor, packaging and common management is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N06 · Are concomitant analgesics, exercise and other treatments distinguished?

Current findings: The original key issue distinguishes WOMAC, VAS and analgesic use. The advertising assessment states that analgesic-replacement claims exceed the trial scope.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original analgesic maintenance/use, rescue-medication rules, exercise/rehabilitation and changes to additional treatment are needed. Efficacy is not extended to an isolated seed-oil effect or drug replacement.
Required materials and conditions: Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes
Materials to obtain first: Additional material needed: Original analgesic maintenance/use, rescue-medication rules, exercise/rehabilitation and changes to additional treatment are needed. Efficacy is not extended to an isolated seed-oil effect or drug replacement.
Further research: Material needed: Original analgesic maintenance/use, rescue-medication rules, exercise/rehabilitation and changes to additional treatment are needed. Efficacy is not extended to an isolated seed-oil effect or drug replacement. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Arm-specific arrangements for baseline treatment, rescue analgesics, exercise/rehabilitation and changes is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N07 · What reporting units do the principal trial and review represent?

Current findings: R01 is the 2022 Huseini original trial; R02 is the 2024 systematic review. The reports are not counted as independent original trials.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: The review’s included articles, registration, additional reports and links to R01 are needed. Recitation of the same original trial is unconfirmed.
Required materials and conditions: Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review
Materials to obtain first: Additional material needed: The review’s included articles, registration, additional reports and links to R01 are needed. Recitation of the same original trial is unconfirmed.
Further research: Material needed: The review’s included articles, registration, additional reports and links to R01 are needed. Recitation of the same original trial is unconfirmed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Bibliography and inclusion correspondence for the Huseini original trial and the 2024 review is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N08 · What arm-specific denominators are represented by 116 randomized participants?

Current findings: R01 records 116 randomized participants and 52 versus 54 completers. Total randomization remains distinct from completion; completion counts are not converted into arm-specific randomized counts.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Arm labels and correspondence with randomized, analyzed and completion counts, plus WOMAC analysis denominators, are needed. Missing-person counts and effects are not newly calculated.
Required materials and conditions: Total randomization and arm-specific randomized/analysis denominators
Materials to obtain first: Additional material needed: Arm labels and correspondence with randomized, analyzed and completion counts, plus WOMAC analysis denominators, are needed. Missing-person counts and effects are not newly calculated.
Further research: Material needed: Arm labels and correspondence with randomized, analyzed and completion counts, plus WOMAC analysis denominators, are needed. Missing-person counts and effects are not newly calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Total randomization and arm-specific randomized/analysis denominators must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Total randomization and arm-specific randomized/analysis denominators is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N09 · What is known about completers, missing data, withdrawals and analysis sets?

Current findings: The 52 versus 54 counts describe completion. The retained sample description does not specify arm labels, ITT/completer analyses or withdrawal reasons.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original flow diagrams, exclusion/discontinuation reasons, missing WOMAC measurements, missing-data handling and sensitivity material are needed. Unread material is not converted into an absence of missing data.
Required materials and conditions: Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers
Materials to obtain first: Additional material needed: Original flow diagrams, exclusion/discontinuation reasons, missing WOMAC measurements, missing-data handling and sensitivity material are needed. Unread material is not converted into an absence of missing data.
Further research: Material needed: Original flow diagrams, exclusion/discontinuation reasons, missing WOMAC measurements, missing-data handling and sensitivity material are needed. Unread material is not converted into an absence of missing data. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Arm correspondence and analysis/missing-data arrangements for 52 versus 54 completers is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N10 · Are total WOMAC and its three domains distinguished?

Current findings: The principal endpoint is total WOMAC with pain, stiffness and function domains. The original key issue distinguishes total score from the pain domain.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original scale versions, score ranges, assessment timing and effects/denominators for each domain are needed. Total-score percentage reduction is not replicated as values for all domains.
Required materials and conditions: Separate scales/ranges/timing for total score, pain, stiffness and function
Materials to obtain first: Additional material needed: Original scale versions, score ranges, assessment timing and effects/denominators for each domain are needed. Total-score percentage reduction is not replicated as values for all domains.
Further research: Material needed: Original scale versions, score ranges, assessment timing and effects/denominators for each domain are needed. Total-score percentage reduction is not replicated as values for all domains. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Separate scales/ranges/timing for total score, pain, stiffness and function must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Separate scales/ranges/timing for total score, pain, stiffness and function is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N11 · What do the original WOMAC reductions represent?

Current findings: R01 retains WOMAC reductions of 27.72±18.61% versus 1.34±2.31%, P<.001; the original record describes the exact between-group CI as unreported.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original definitions of means/dispersion, baseline/change values, denominators and statistical methods are needed. ± is not arbitrarily converted into CI/SE, and no new between-group difference is calculated.
Required materials and conditions: Arm-specific percentage reductions, original ± notation and measurement/calculation definitions
Materials to obtain first: Additional material needed: Original definitions of means/dispersion, baseline/change values, denominators and statistical methods are needed. ± is not arbitrarily converted into CI/SE, and no new between-group difference is calculated.
Further research: Material needed: Original definitions of means/dispersion, baseline/change values, denominators and statistical methods are needed. ± is not arbitrarily converted into CI/SE, and no new between-group difference is calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Arm-specific percentage reductions, original ± notation and measurement/calculation definitions must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Arm-specific percentage reductions, original ± notation and measurement/calculation definitions is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N12 · Are the exact adjusted between-group difference and 95% CI available?

Current findings: The original reader answer describes the exact adjusted between-group difference and 95% CI as unreported. The result table retains the original label that the exact between-group CI is unreported.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original between-group analysis tables, adjustment variables, variance and CIs are needed. Unreported information in the original summary remains distinct from current external nonreading; numbers are not reverse-calculated.
Required materials and conditions: Adjusted/unadjusted between-group effects and 95% CI
Materials to obtain first: Additional material needed: Original between-group analysis tables, adjustment variables, variance and CIs are needed. Unreported information in the original summary remains distinct from current external nonreading; numbers are not reverse-calculated.
Further research: Material needed: Original between-group analysis tables, adjustment variables, variance and CIs are needed. Unreported information in the original summary remains distinct from current external nonreading; numbers are not reverse-calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Adjusted/unadjusted between-group effects and 95% CI must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Adjusted/unadjusted between-group effects and 95% CI is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N13 · What endpoint and comparison does P<.001 concern?

Current findings: P<.001 is retained with the original WOMAC percentage-reduction result. It is not replicated as a P value for VAS, all domains or long-term results.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original tests, primary endpoints/timing, multiplicity, analysis sets and adjustment arrangements are needed.
Required materials and conditions: Original between-group WOMAC testing and multiplicity/analysis plans
Materials to obtain first: Additional material needed: Original tests, primary endpoints/timing, multiplicity, analysis sets and adjustment arrangements are needed.
Further research: Material needed: Original tests, primary endpoints/timing, multiplicity, analysis sets and adjustment arrangements are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Original between-group WOMAC testing and multiplicity/analysis plans must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original between-group WOMAC testing and multiplicity/analysis plans is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N14 · Are 1-month results distinguished from sustained and post-discontinuation effects?

Current findings: The original duration is 1 month of treatment and follow-up. The original rationale states that this is a symptom signal rather than cartilage protection or a sustained effect.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Longer follow-up, post-discontinuation course and repeat trials of the same formulation are needed. A 1-month result is not converted into a long-term effect.
Required materials and conditions: The original 1 month of treatment/follow-up and separate later material
Materials to obtain first: Additional material needed: Longer follow-up, post-discontinuation course and repeat trials of the same formulation are needed. A 1-month result is not converted into a long-term effect.
Further research: Material needed: Longer follow-up, post-discontinuation course and repeat trials of the same formulation are needed. A 1-month result is not converted into a long-term effect. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on The original 1 month of treatment/follow-up and separate later material must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on The original 1 month of treatment/follow-up and separate later material is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N15 · Are the original allocation and masking methods known?

Current findings: R01 is described as a randomized, double-blind, placebo-controlled trial. Original methodological details, successful masking and suitability remain unverified here.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original methods, registration/plans and masking material are needed. No formal RoB2 result or new suitability judgment is created.
Required materials and conditions: Random sequence, concealment and participant/assessor masking
Materials to obtain first: Additional material needed: Original methods, registration/plans and masking material are needed. No formal RoB2 result or new suitability judgment is created.
Further research: Material needed: Original methods, registration/plans and masking material are needed. No formal RoB2 result or new suitability judgment is created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Random sequence, concealment and participant/assessor masking must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Random sequence, concealment and participant/assessor masking is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N16 · Are the prospective WOMAC hierarchy and reporting selection confirmed?

Current findings: The stored evidence describes WOMAC as principal and VAS and other outcomes as secondary. Registration status is unconfirmed. The original prospective plan remains unread here.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Registration, protocols/SAPs, original endpoint tables and all reported time points are needed. A summary selecting a principal outcome is not promoted to confirmed preregistration.
Required materials and conditions: Prospective plans for primary endpoints, domains, VAS and timing
Materials to obtain first: Additional material needed: Registration, protocols/SAPs, original endpoint tables and all reported time points are needed. A summary selecting a principal outcome is not promoted to confirmed preregistration.
Further research: Material needed: Registration, protocols/SAPs, original endpoint tables and all reported time points are needed. A summary selecting a principal outcome is not promoted to confirmed preregistration. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Prospective plans for primary endpoints, domains, VAS and timing must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Prospective plans for primary endpoints, domains, VAS and timing is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N17 · Is concordant VAS direction retained as a separate endpoint?

Current findings: The original counterview describes concordant WOMAC and VAS directions. VAS is secondary; specific VAS values are absent from the retained result.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original VAS results and prospective hierarchy are needed. WOMAC reductions and gaps in P values/CIs are not transferred into VAS values.
Required materials and conditions: Separate VAS effects, CIs, denominators and timing
Materials to obtain first: Additional material needed: Original VAS results and prospective hierarchy are needed. WOMAC reductions and gaps in P values/CIs are not transferred into VAS values.
Further research: Material needed: Original VAS results and prospective hierarchy are needed. WOMAC reductions and gaps in P values/CIs are not transferred into VAS values. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Separate VAS effects, CIs, denominators and timing must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Separate VAS effects, CIs, denominators and timing is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N18 · Are analgesic-use results separate from WOMAC?

Current findings: The original key issue distinguishes analgesic use from total score, pain and VAS. Structured evidence does not contain numeric analgesic-use results.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original amounts used, rescue-medication rules, prospective hierarchy and result tables are needed. An analgesic-replacement effect is not established.
Required materials and conditions: Rescue-medication definitions, timing and arm-specific effects/denominators
Materials to obtain first: Additional material needed: Original amounts used, rescue-medication rules, prospective hierarchy and result tables are needed. An analgesic-replacement effect is not established.
Further research: Material needed: Original amounts used, rescue-medication rules, prospective hierarchy and result tables are needed. An analgesic-replacement effect is not established. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Rescue-medication definitions, timing and arm-specific effects/denominators must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Rescue-medication definitions, timing and arm-specific effects/denominators is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N19 · Are patient importance and responder effects known?

Current findings: The original grade rationale describes a positive patient-symptom-scale signal. Exact CIs, responder rates and prospective importance thresholds are absent from the structured summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original importance criteria, responder definitions/denominators and CIs are needed. Percentage reduction alone is not used for a new judgment of clinically large effects or treatment success.
Required materials and conditions: WOMAC importance thresholds and prospectively defined responder results
Materials to obtain first: Additional material needed: Original importance criteria, responder definitions/denominators and CIs are needed. Percentage reduction alone is not used for a new judgment of clinically large effects or treatment success.
Further research: Material needed: Original importance criteria, responder definitions/denominators and CIs are needed. Percentage reduction alone is not used for a new judgment of clinically large effects or treatment success. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on WOMAC importance thresholds and prospectively defined responder results must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on WOMAC importance thresholds and prospectively defined responder results is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N20 · What is the scope of the review’s 6 RCTs and 370 participants?

Current findings: R02 records 6 RCTs and 370 participants, mixing oral and topical routes. These are not converted into 6 independent trials of oral liquid seed oil or WOMAC analysis denominators.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Inclusion tables by route, formulation, original-trial family, endpoint and timing are needed. The 116 and 370 participants are not summed.
Required materials and conditions: Included material and endpoint-specific denominators in the mixed oral/topical review
Materials to obtain first: Additional material needed: Inclusion tables by route, formulation, original-trial family, endpoint and timing are needed. The 116 and 370 participants are not summed.
Further research: Material needed: Inclusion tables by route, formulation, original-trial family, endpoint and timing are needed. The 116 and 370 participants are not summed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Included material and endpoint-specific denominators in the mixed oral/topical review must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Included material and endpoint-specific denominators in the mixed oral/topical review is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N21 · Is the finding of a positive oral-oil result in one of two trials retained?

Current findings: R02 records a positive oral-oil finding in one of two trials, with mixed other oral/topical results. This is not presented as confirmed replication of the same formulation.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Identifiers, doses, endpoints/timing, effects, denominators and inclusion relationships for the two trials are needed. Numbers/CIs for another unidentified trial are not invented.
Required materials and conditions: Formulations, populations, timing and effects/CIs in the two oral-oil trials
Materials to obtain first: Additional material needed: Identifiers, doses, endpoints/timing, effects, denominators and inclusion relationships for the two trials are needed. Numbers/CIs for another unidentified trial are not invented.
Further research: Material needed: Identifiers, doses, endpoints/timing, effects, denominators and inclusion relationships for the two trials are needed. Numbers/CIs for another unidentified trial are not invented. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Formulations, populations, timing and effects/CIs in the two oral-oil trials must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Formulations, populations, timing and effects/CIs in the two oral-oil trials is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N22 · Are topical oil, oral capsules and rheumatoid-arthritis material separated?

Current findings: The original research description excludes topical oil/rheumatoid-arthritis material, while the original supplementary note states that topical oil and oral capsules are not identical replications.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original review tables by route, formulation and disease are needed. These are not combined as independent replication or equivalence for this oral liquid seed oil.
Required materials and conditions: Eligibility boundaries by route, formulation and disease
Materials to obtain first: Additional material needed: Original review tables by route, formulation and disease are needed. These are not combined as independent replication or equivalence for this oral liquid seed oil.
Further research: Material needed: Original review tables by route, formulation and disease are needed. These are not combined as independent replication or equivalence for this oral liquid seed oil. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Eligibility boundaries by route, formulation and disease must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Eligibility boundaries by route, formulation and disease is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N23 · Are independent teams and unique trial/participant counts certified?

Current findings: The original principal verdict retains a single principal study and limited replication. The current reports represent an original trial and a review; shared-trial correspondence is unconfirmed.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Teams, institutions, funding, identical samples and original-trial/additional-report lists are needed. Final unique-trial and participant totals remain null.
Required materials and conditions: Original-trial families and overlap/independence links for the same question
Materials to obtain first: Additional material needed: Teams, institutions, funding, identical samples and original-trial/additional-report lists are needed. Final unique-trial and participant totals remain null.
Further research: Material needed: Teams, institutions, funding, identical samples and original-trial/additional-report lists are needed. Final unique-trial and participant totals remain null. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Original-trial families and overlap/independence links for the same question must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original-trial families and overlap/independence links for the same question is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N24 · Are cartilage protection, disease modification and analgesic replacement separate questions?

Current findings: The original rationale/advertising assessment does not extend a 1-month symptom signal to cartilage protection, regeneration, disease modification or analgesic replacement.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Direct comparisons of imaging/structural endpoints, long-term clinical course and drug replacement are needed. Those efficacy claims are not added here.
Required materials and conditions: Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement
Materials to obtain first: Additional material needed: Direct comparisons of imaging/structural endpoints, long-term clinical course and drug replacement are needed. Those efficacy claims are not added here.
Further research: Material needed: Direct comparisons of imaging/structural endpoints, long-term clinical course and drug replacement are needed. Those efficacy claims are not added here. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Direct material distinguishing symptom scales from structural/disease-modifying effects and drug replacement is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N25 · Are the four channels of company involvement known separately?

Current findings: R01 records unconfirmed funding/product-involvement details; R02 records differing funding across individual trials. Generic English funding wording remains distinct from complete item-specific material.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Original support, product provision, author affiliations and COI are needed. Unverified information is not converted into a noncommercial/independence strength.
Required materials and conditions: Trial/review-specific funding, product support, employee authorship and COI
Materials to obtain first: Additional material needed: Original support, product provision, author affiliations and COI are needed. Unverified information is not converted into a noncommercial/independence strength.
Further research: Material needed: Original support, product provision, author affiliations and COI are needed. Unverified information is not converted into a noncommercial/independence strength. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Trial/review-specific funding, product support, employee authorship and COI must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Trial/review-specific funding, product support, employee authorship and COI is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N26 · Are harm-collection methods, discontinuations and events known?

Current findings: The original safety label is Caution, and small trials cannot exclude rare adverse events or establish long-term safety. Specific harm-collection methods/event tables are absent from stored summaries.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Active/passive collection, events, discontinuations and missing-data material are needed. Unread material is not presented as an absence of adverse events.
Required materials and conditions: Adverse-event definitions, collection, severity and original event tables
Materials to obtain first: Additional material needed: Active/passive collection, events, discontinuations and missing-data material are needed. Unread material is not presented as an absence of adverse events.
Further research: Material needed: Active/passive collection, events, discontinuations and missing-data material are needed. Unread material is not presented as an absence of adverse events. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Adverse-event definitions, collection, severity and original event tables must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Adverse-event definitions, collection, severity and original event tables is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N27 · What are the harm denominators and exposure durations?

Current findings: The 116 randomized participants and 52 versus 54 completers do not establish safety denominators. Exposure for 1 month is not long-term harm evidence.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Arm-specific safety sets, administration/discontinuation, event counts, exposure time and control-group records are needed. No new incidence is calculated.
Required materials and conditions: Safety denominators, actual administration and arm-specific events/exposure
Materials to obtain first: Additional material needed: Arm-specific safety sets, administration/discontinuation, event counts, exposure time and control-group records are needed. No new incidence is calculated.
Further research: Material needed: Arm-specific safety sets, administration/discontinuation, event counts, exposure time and control-group records are needed. No new incidence is calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Safety denominators, actual administration and arm-specific events/exposure must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Safety denominators, actual administration and arm-specific events/exposure is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N28 · What is known about concomitant medicines, other causes and event timing?

Current findings: The original safety description contains cautions calling for consultation during use of those medicines. This does not confirm actual drug-specific interactions or causal harms.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Concomitant medicines, baseline diseases, event timing, changes, controls and post-discontinuation course are needed. New drug-specific causal judgments are not created.
Required materials and conditions: Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes
Materials to obtain first: Additional material needed: Concomitant medicines, baseline diseases, event timing, changes, controls and post-discontinuation course are needed. New drug-specific causal judgments are not created.
Further research: Material needed: Concomitant medicines, baseline diseases, event timing, changes, controls and post-discontinuation course are needed. New drug-specific causal judgments are not created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Glucose-, blood-pressure-, anticoagulant-, antiseizure- and immune-modifying drugs and other causes is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N29 · Are long-term, rare and vulnerable-population harms verified?

Current findings: The original text retains consultation cautions for pregnancy/breastfeeding, children, liver/kidney disease and surgery, and the inability to exclude rare/long-term harms. This is not promoted to safety certification.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: Longer follow-up, vulnerable populations, independent reports and exposure/denominator material are needed. No new harm search or reassessment is performed.
Required materials and conditions: Independent harm reports, long-term/rare events, vulnerable groups and exposure
Materials to obtain first: Additional material needed: Longer follow-up, vulnerable populations, independent reports and exposure/denominator material are needed. No new harm search or reassessment is performed.
Further research: Material needed: Longer follow-up, vulnerable populations, independent reports and exposure/denominator material are needed. No new harm search or reassessment is performed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Independent harm reports, long-term/rare events, vulnerable groups and exposure must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Independent harm reports, long-term/rare events, vulnerable groups and exposure is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N30 · Are actual stored-summary reading and original-source links distinguished?

Current findings: The complete stored summary was read for preparation; the two PubMed URLs and review PMCID are retained records. External abstracts, full text, registration and protocols/SAPs remain unread here.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: External material remains unread before user-provided acquisition and review. A PMCID/URL alone is not promoted to access, reading or fulfilled conditions.
Required materials and conditions: Access table for stored summaries, abstracts, full text, registration and protocols/SAPs
Materials to obtain first: Additional material needed: External material remains unread before user-provided acquisition and review. A PMCID/URL alone is not promoted to access, reading or fulfilled conditions.
Further research: Material needed: External material remains unread before user-provided acquisition and review. A PMCID/URL alone is not promoted to access, reading or fulfilled conditions. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Access table for stored summaries, abstracts, full text, registration and protocols/SAPs must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Access table for stored summaries, abstracts, full text, registration and protocols/SAPs is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N31 · Are generic English wording and the historical correction preserved?

Current findings: The correction records changes to 2 English-placeholder fields while preserving original values. Remaining generic English wording on sample size, results and funding is preserved in the original and is not presented as newly completed content review.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: The original correction-target comparison and external English texts remain unverified here. Current preparation remains distinct from historical verification wording.
Required materials and conditions: The full Korean/English record and targets/limits of the 2026-09-14 correction
Materials to obtain first: Additional material needed: The original correction-target comparison and external English texts remain unverified here. Current preparation remains distinct from historical verification wording.
Further research: Material needed: The original correction-target comparison and external English texts remain unverified here. Current preparation remains distinct from historical verification wording. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on The full Korean/English record and targets/limits of the 2026-09-14 correction must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on The full Korean/English record and targets/limits of the 2026-09-14 correction is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02

N32 · Are original grades, axes, evidence date and production distinguished?

Current findings: C/50/Caution, original axes and the evidence date 2026-09-08 are retained. This preparation is not a new efficacy grade, independent certification or formal-method certification.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: What remains unverified in stored summaries: New evidence, condition revisions and verdict changes are separate events after user review. Original dates are not converted into a current search end date or external-reading date.
Required materials and conditions: Original C50, Caution, axes, evidence date and correction values
Materials to obtain first: Additional material needed: New evidence, condition revisions and verdict changes are separate events after user review. Original dates are not converted into a current search end date or external-reading date.
Further research: Material needed: New evidence, condition revisions and verdict changes are separate events after user review. Original dates are not converted into a current search end date or external-reading date. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in original denominators and arm correspondence, missing data, WOMAC measurement and dispersion, exact between-group effects and intervals, prospective analyses, review inclusion and overlap, support and harms. Original numbers and grades do not constitute new calculations, reassessment or clinical validation.
Conditions for verification: Original records on Original C50, Caution, axes, evidence date and correction values must link to the relevant report, original trial, analysis unit, timing and denominator, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original C50, Caution, axes, evidence date and correction values is needed to connect the relevant formulation, route, population, comparison, WOMAC endpoint, timing, denominator or harm scope.
Application exceptions: Total WOMAC, its domains, VAS and analgesic use remain distinct, as do randomized, analyzed, completion and harm denominators. Short-term symptom results are not extended to other formulations, routes, diseases, cartilage protection, long-term effects, drug replacement or overall safety.
Referenced methods: Existing principles distinguish formulation, route, population, WOMAC endpoints, timing, randomized/analyzed/completion denominators, original trials versus reviews, overlap, support and harms in the retained knee-osteoarthritis record.

Related sources R01 R02